HER2-positive Carcinoma Completed Phase 1 Trials for Pertuzumab (DB06366)

IndicationStatusPhase
DBCOND0088269 (HER2-positive Carcinoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03109977Imaging With a New Agent That Finds a Cancer Protein Called HER2Diagnostic